Dyslexia—A trial of medication to treat Dyslexia, with or without ADHD
Description
The study will evaluate a drug called Atomoxetine (Strattera) for children 10-16 years old with Dyslexia (reading disability). Subjects may also have ADHD, but this is not required. Currently Atomoxetine is FDA approved for the treatment of ADHD. The medication or placebo will be administered at 1.0 to 1.4 mg/kg/day given orally once daily in the morning.
Study Design
- Comprehensive diagnostic evaluation and psychoeducational testing, with written report.
- 16 weeks Double Blind Study followed by 16 weeks Open-Label study medication.
- No charge to participate. Enrollment is ongoing.
Participant Requirements
- Child or adolescent patients must be 10 to 16 years old
- Child or adolescent who weighs 55 to 150 lbs
- Child or adolescent diagnosed or suspected to have Dyslexia, OR reading significantly below grade level, OR diagnosed or suspected to have ADHD
Payment
$40 for each clinic visit